The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Bevacizumab (BEV) plus capecitabine as maintenance therapy after initial treatment with BEV plus XELOX in previously untreated patients (pts) with metastatic colorectal cancer (mCRC): Mature data from STOP and GO, a phase III, randomized, multicenter study.
Suayib Yalcin
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Ruchan Uslu
Honoraria - Roche
Research Funding - Roche
Faysal Dane
Honoraria - Roche
Research Funding - Roche
Ugur Yilmaz
Honoraria - Roche
Research Funding - Roche
Nurullah Zengin
Honoraria - Roche
Research Funding - Roche
Evin Buyukunal
Honoraria - Roche
Research Funding - Roche
Suleyman Buyukberber
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Celalettin Camci
Honoraria - Roche
Research Funding - Roche
Orhan Sencan
Honoraria - Roche
Research Funding - Roche
Saadettin Kilickap
Honoraria - Roche
Research Funding - Roche
Fatih Ozdener
Employment or Leadership Position - Roche
Duygu Cevik
Employment or Leadership Position - Roche